Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-702-7 | CAS number: 109-76-2
Carcinogenicity
Administrative data
Description of key information
There is no evidence of carcinogenicity by dermal or oral route exposure to triethylenediamine based on read across to test results generated in carcinogenicity studies with ethylenediamine and ethylene diammonium chloride.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 195 mg/kg bw/day
Carcinogenicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 10.2 mg/kg bw/day
Justification for classification or non-classification
No carcinogenic effects have been observed in studies with ethylenediamine and ethylene diammonium chloride. A read across approach is justified as trimethylenediamine is structural very similar to ethylenediamine (difference: chain length / one CH2-group) or ethylenediammonium dichloride (applied doses of ammonium and chloride of no toxicological relevance), respectively. Thus, there is no evidence that trimethylenediamine has carcinogenic potential and is thus not classified in accordance to Directive 67/548/EEC (DSD) and Regulation (EC) No 1271/2008 (GHS).
Additional information
Oral route
In a 2 year combined chronic toxicity and carcinogenicity study, Fischer 344 rats were dosed with ethylene diammonium chloride via diet (Hermansky, 1999). There is no evidence, under the conditions of this study, that chronic feeding of ethylenediamine dihydrochloride - and based on a read across approach of triethylenediamine - exhibited a carcinogenic effect in the Fischer 344 rat up to the highest dose tested (350 mg/kg/day of EDA*2HCl, equivalent to 195 mg/kg/day triethylenediamine).
Dermal route
The dermal oncogenic potential of ethylenediamine (EDA) was assessed on male CH3 mice.The doses of EDA were selected in preliminary 2-week studies in which various concentrations, 1 to 10%, were applied daily. The skin was closely observed for signs of irritation, and the mice were weighed several times to assess any effects on weight gain. Application of a 5% solution resulted in open sores on the skin of 80% of the treated mice. The 1% solution was the highest EDA concentration which resulted in neither gross skin irritation nor reduced weight gain and was, therefore, chosen for the lifetime dermal carcinogenicity study in 50 male mice (application of 25 µL three times a week). Two EDA samples (purity 99.91% and 99.1%) from different producers were tested. A negative control group was treated with water only and a positive control group received 0,1% 3 -methylcholanthrene in acetone. No skin tumours were observed in the EDA treated animals. In the positive control group 98% of the animals had skin tumours (DePass, 1984).
Based on this study the dermal carcinogenic NOAEL was calculated to be 10.2 mg/kg bw/day trimethylenediamine (actually received dose).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
